Cart
sales@molnova.com
Pyridoxine
CAS No. 65-23-6
Pyridoxine( —— )
Catalog No. M15477 CAS No. 65-23-6
Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 35 | In Stock |
|
| 500MG | 82 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePyridoxine
-
NoteResearch use only, not for human use.
-
Brief DescriptionPyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body.
-
DescriptionPyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading. (In Vitro):Pyridoxine exerts a protective potential against AD, attenuates ROS levels, decreases the expressions of cytoplasmic Nrf2, and upregulates whole-cell HO-1 expression.
-
In VitroPyridoxine exerts a protective potential against AD, attenuates ROS levels, decreases the expressions of cytoplasmic Nrf2, and upregulates whole-cell HO-1 expression.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPLK
-
RecptorPLK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number65-23-6
-
Formula Weight169.18
-
Molecular FormulaC8H11NO3
-
Purity>98% (HPLC)
-
SolubilitySoluble in Water
-
SMILESCC1=NC=C(CO)C(CO)=C1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Adams JB, et al. J Altern Complement Med. 2006 Jan-Feb;12(1):59-63.
molnova catalog
related products
-
Centrinone-B
Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor with a Ki of 0.59 nM.
-
Poloxin-2
Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells.
-
GSK-461364
A potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM.
